Trade with Eva : Analytics in action

Thursday, October 17, 2024

===ASP Isotopes (ASPI) enriches ytterbium-176

ASP Isotopes enriches ytterbium-176 during commissioning phase of first quantum enrichment facility and expects to offer highly enriched ytterbium-176 for commercial sale in 2025

The Company has accelerated the commissioning phase of its first Quantum Enrichment plant and produced the first semi-finished material of enriched Ytterbium-176.
Commissioning phase was initially anticipated to take 3-6 months, but the Company produced enriched Ytterbium-176 during the first 6 weeks.
The Company expects to be able to achieve a 99.75% enrichment for Ytterbium-176 and offer highly enriched Ytterbium-176 for commercial sale during 2025, with samples available during 1Q 2025. Contact details for prospective customers are provided below.
The Company expects to proceed with the plans to construct Nickel-64 and Lithium-6/7 Quantum Enrichment plants with targeted production during 2025.
The Company expects to continue its discussions with government authorities and regulators for the authorization to construct HALEU uranium enrichment facilities using Quantum Enrichment.

==Amicus Therapeutics (FOLD) has entered into a License Agreement with Teva Pharmaceuticals (TEVA)

Amicus Therapeutics has entered into a License Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc.

This Agreement resolves the patent litigation brought by Amicus in response to Teva's Abbreviated New Drug Application seeking approval to market a generic version of GALAFOLD 123mg capsules prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD in the United States beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration and unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding GALAFOLD patents pending in the U.S. District Court for the District of Delaware. The litigation will continue against Aurobindo1 as the remaining active party and the litigation stay remains in place for Lupin.
As required by law, the companies will submit the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

Wednesday, October 16, 2024

MetroCity Bankshares (MCBS) increases quarterly cash dividend to $0.23/share

MetroCity Bankshares increases quarterly cash dividend to $0.23/share from $0.20/share and announces the continuation of its share repurchase program

The Company approves the continuation of its share repurchase program that expired on September 30, 2024 and authorized the Company to repurchase up to 925,250 shares of the Company's outstanding shares of common stock, which is the number of remaining shares authorized for repurchase from the Prior Share Repurchase Plan.
The share repurchase program will begin on October 17, 2024 and end on September 30, 2025.